Trademark Overview
On Friday, July 19, 2024, a trademark application was filed for ABILEAP with the United States Patent and Trademark Office. The USPTO has given the ABILEAP trademark a serial number of 98657918. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, February 5, 2025. This trademark is owned by ABILITY BIOLOGICS INC. The ABILEAP trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:
antibody products and molecules acting as immune modulators for scientific and medical purposes; colostral antibodies for medical purposes; pharmaceutical antibodies for the treatment of hereditary angioedema (HAE); pharmaceutical antibodies for the treatment of respiratory diseases and respiratory syndromes; pharmaceutical antibody preparations for auto-immune diseases; pharmaceutical antibody preparations for the prevention and treatment of auto-immune diseases; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories;
antibody products and molecules for scientific and medical purposes;
antibody profiling for scientific research purposes, for discovery and development of new biotherapeutics; operation of scientific database and website regarding research in the fields of cancer, immunology, inflammation, biologics, antibodies and molecules; molecule development; clinical trials; providing temporary use of a non-downloadable software for managing information in the fields of cancer, immunology, inflammation, biologics, antibodies and molecules; Platform as a service [PaaS] for analyzing molecular and clinical data to develop antibodies against immune targets; analysis in the field of molecular biology; molecular analysis and product optimization for the purpose of pharmaceutical development;
